{"id":"degarelix-lhrh-antagonist","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site reactions"},{"rate":"25-30","effect":"Hot flashes"},{"rate":"10-15","effect":"Weight gain"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Gynecomastia"},{"rate":null,"effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL415606","moleculeType":"Protein","molecularWeight":"1632.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unlike GnRH agonists that cause initial testosterone surge before suppression, degarelix directly blocks GnRH receptors on pituitary gonadotroph cells, achieving rapid and sustained testosterone reduction without a flare effect. This makes it particularly useful in prostate cancer where testosterone flare can exacerbate symptoms.","oneSentence":"Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist that rapidly suppresses luteinizing hormone and follicle-stimulating hormone, leading to testosterone suppression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:12.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Hormone-responsive prostate cancer"}]},"trialDetails":[{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT04989946","phase":"PHASE1, PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT03703778","phase":"","title":"Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2016-05-22","conditions":"Prostate Cancer","enrollment":300},{"nctId":"NCT05057546","phase":"PHASE4","title":"Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-11-22","conditions":"Menopause, Estrogen Deficiency, Women","enrollment":55},{"nctId":"NCT01994239","phase":"PHASE2","title":"Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-12","conditions":"Adenocarcinoma of Prostate","enrollment":120},{"nctId":"NCT06264882","phase":"PHASE4","title":"Cardiometabolic Consequences of the Loss of Ovarian Function","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-06-01","conditions":"Menopause, Estrogen Deficiency, Aging","enrollment":100},{"nctId":"NCT03358563","phase":"EARLY_PHASE1","title":"Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-17","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT01712763","phase":"PHASE3","title":"Degarelix in the Treatment of Endometriosis Recurrence","status":"COMPLETED","sponsor":"Centre for Endocrinology and Reproductive Medicine, Italy","startDate":"2012-11","conditions":"Endometriosis","enrollment":360},{"nctId":"NCT03899077","phase":"PHASE2","title":"Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP","status":"UNKNOWN","sponsor":"Cancer Research Antwerp","startDate":"2019-04-05","conditions":"Cancer of Prostate","enrollment":202},{"nctId":"NCT04043520","phase":"PHASE4","title":"Bioenergetic Effects of Aging and Menopause (BEAM)","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2019-09-24","conditions":"Menopause, Obesity, Abdominal, Aging","enrollment":57},{"nctId":"NCT06001619","phase":"PHASE4","title":"Prostate Medication, Metabolism and Gut Microbiota","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2022-12-01","conditions":"Prostatic Hyperplasia, Prostate Cancer","enrollment":100},{"nctId":"NCT02663908","phase":"PHASE3","title":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-04-19","conditions":"Prostate Cancer","enrollment":545},{"nctId":"NCT04248621","phase":"PHASE4","title":"Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients","status":"UNKNOWN","sponsor":"Wonju Severance Christian Hospital","startDate":"2020-01-23","conditions":"Prostatic Neoplasms","enrollment":164},{"nctId":"NCT03112226","phase":"NA","title":"Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-02-07","conditions":"Cognitive Impairment, Estrogen Deficiency, Menopause","enrollment":19},{"nctId":"NCT03876912","phase":"NA","title":"The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2019-03-01","conditions":"Prostate Cancer","enrollment":35},{"nctId":"NCT04134130","phase":"NA","title":"The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Lund University","startDate":"2019-09-16","conditions":"Prostate Cancer Recurrent","enrollment":33},{"nctId":"NCT04182594","phase":"PHASE2","title":"Cardiovascular Events in GnRH Agonist vs. Antagonist","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2020-01-17","conditions":"Hormone Sensitive Prostate Cancer, Prostate Cancer, Cardiac Event","enrollment":80},{"nctId":"NCT02324998","phase":"PHASE1","title":"Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2016-12","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT02475057","phase":"PHASE4","title":"Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2015-08","conditions":"Prostatic Neoplasms, Cardiovascular Diseases","enrollment":80},{"nctId":"NCT01696877","phase":"PHASE1, PHASE2","title":"A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-01-18","conditions":"Prostate Cancer Adenocarcinoma in Situ","enrollment":29},{"nctId":"NCT02135445","phase":"PHASE2","title":"Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Prostate Cancer","enrollment":103},{"nctId":"NCT00527488","phase":"PHASE2","title":"Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-10","conditions":"BPH","enrollment":52},{"nctId":"NCT01630967","phase":"PHASE2","title":"Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2012-08","conditions":"Prostate Neoplasm","enrollment":40},{"nctId":"NCT00434122","phase":"PHASE2","title":"Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-03","conditions":"Infertility, Female","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Firmagon"],"phase":"marketed","status":"active","brandName":"Degarelix (LHRH antagonist)","genericName":"Degarelix (LHRH antagonist)","companyName":"Rabin Medical Center","companyId":"rabin-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist that rapidly suppresses luteinizing hormone and follicle-stimulating hormone, leading to testosterone suppression. Used for Advanced prostate cancer, Hormone-responsive prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}